cordis


Also found in: Acronyms, Wikipedia.

cor·dis

(kōr'dis),
Of the heart.
[gen. of L. cor, heart]
References in periodicals archive ?
We are pleased that the FDA warning letter is now resolved," said Rick Anderson, Company Group Chairman, Cordis Corporation.
We are pleased to announce this distribution agreement with Cordis Corporation to provide interventional cardiologists with the tools they need every day in the treatment of the millions of patients around the world with coronary artery disease," said Andrew Jones, Chief Executive Officer, ClearStream Technologies Group, plc.
Cordis Cardiology, based at the Cordis headquarters in Miami Lakes, is the company's largest business and manufactures diagnostic, interventional products and stents.
The CORDIS ENTERPRISE(TM) Vascular Reconstruction Device is a new self- expanding, closed cell design, nitinol stent with good visible proximal and distal markers and an added feature of a horizontal longitudinal marker on the delivery wire to facilitate delivery.
Patients treated with later generations of Cordis drug-eluting stents will also be enrolled as stents become commercially available.
These products were found to infringe two Cordis patents commonly known as the '762 and '984 patents.
As the leader in cardiology and vascular health, we are in a unique position to help physicians and other health care professionals to significantly advance the treatment of cardiac and vascular disease," said Rick Anderson, Company Group Chairman, Johnson & Johnson and Worldwide Franchise Chairman, Cordis Corporation.
March 30 /PRNewswire/ -- Cordis Corporation, a worldwide leader in developing and manufacturing interventional vascular technology, announced today the start of the pivotal trial for the ExoSeal(TM) Vascular Closure Device.
MIAMI, June 9 /PRNewswire/ -- Cordis Corporation, a Johnson & Johnson company, today received a ruling from a court in the Netherlands that found the company infringed a Boston Scientific patent related to a catheter shaft that is used in the delivery system for the CYPHER(R) and CYPHER(R) Select Sirolimus-eluting Coronary Stents, as well as several other catheter-based products.
OTCBB:XRYM), an industry leader in real-time negotiating technology, is pleased to announce that the company has been granted a license from the Bureau of the European Community Research and Development Information Services, CORDIS unit.
Cordis is offering the REGATTA(TM) Guidewire family to provide tailored solutions for the placement of catheters and other interventional devices in coronary arteries.
SAN DIEGO -- IT&E International Group (OTCBB:ITER), announced today that it has signed a long-term, multi-country agreement with Cordis Corporation, a Johnson & Johnson (NYSE:JNJ) company, for expanded FDA regulatory compliance services.